EDIT
Editas Medicine, Inc.
$3.04
-0.12 (-3.80%)
At close · Jul 15
Market Cap
$297.15M
Shares
97,906,282
Income-statement, balance-sheet and cash-flow figures extracted from the company's SEC filings — 10-K annual and 10-Q quarterly reports — and standardised for comparison across periods.
Revenue
$40.52M
+25.4%
FY2025
Net Income
-$160.06M
+32.5%
FY2025
Operating Margin
-394.89%
+382.3pp
FY2025
Diluted EPS
-$1.80
+37.5%
FY2025
Operating Cash Flow
-$165.24M
+21.4%
FY2025
Chart any reported metric, KPI or segment over time — the full statement history lives here
Search above to add metrics — fundamentals, product and segment revenue, company KPIs, valuation.
| Line Item | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | FY2015 | FY2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| $38.69M | $40.52M | $32.31M | $78.12M | $19.71M | $25.54M | $90.73M | $20.53M | $31.94M | $13.73M | $6.05M | — | — | |
| $80.96M | $89.95M | $199.25M | $177.65M | $174.96M | $142.51M | $158M | $96.9M | $90.65M | $83.16M | $56.98M | $18.85M | $5.07M | |
| $46.76M | $49.9M | $71.99M | $69.65M | $70.7M | $76.18M | $67.58M | $64.56M | $55.01M | $50.5M | $46.26M | $18.1M | $7.65M | |
| — | — | $12.23M | $0 | $0 | — | — | — | — | — | — | — | — | |
| $147.54M | $200.53M | $283.47M | $247.3M | $245.66M | $218.69M | $225.57M | $161.45M | $145.66M | $133.66M | $103.24M | $36.94M | $12.72M | |
| -$108.85M | -$160.01M | -$251.15M | -$169.18M | -$225.95M | -$193.15M | -$134.84M | -$140.92M | -$113.73M | -$119.93M | -$97.19M | -$35.31M | -$12.72M | |
| — | -394.89% | -777.22% | -216.56% | -1146.26% | -756.13% | -148.61% | -686.39% | -356.1% | -873.64% | -1605.62% | — | — | |
| — | $2.13M | $0 | — | — | — | — | — | — | — | — | — | — | |
| -$104K | -$50K | $14.06M | $15.96M | $5.52M | $644K | $18.86M | $7.18M | $3.77M | -$391K | $5000 | -$37.59M | -$962K | |
| — | $0 | $0 | $0 | $0 | $0 | — | — | — | — | — | — | — | |
| -$108.95M | -$160.06M | -$237.09M | -$153.22M | -$220.43M | -$192.5M | -$115.98M | -$133.75M | -$109.95M | -$120.32M | -$97.18M | -$72.9M | -$13.69M | |
| — | -395.01% | -733.72% | -196.13% | -1118.26% | -753.61% | -127.82% | -651.43% | -344.28% | -876.49% | -1605.53% | — | — | |
| — | — | — | — | -$220.43M | -$192.5M | -$115.98M | -$133.75M | -$109.95M | -$120.32M | -$97.23M | -$73.29M | -$13.99M | |
| -$109.04M | -$160.33M | -$237.02M | -$149.42M | -$223.54M | -$192.95M | -$116.13M | -$133.61M | -$109.91M | -$120.4M | -$97.18M | -$72.9M | — | |
| USD/shares | — | -$1.80 | -$2.88 | -$2.02 | -$3.21 | -$2.85 | -$1.98 | -$2.68 | — | — | — | — | — |
| USD/shares | — | -$1.80 | -$2.88 | -$2.02 | -$3.21 | -$2.85 | -$1.98 | -$2.68 | — | — | — | — | — |
| shares | — | 88.75M | 82.34M | 75.97M | 68.66M | 67.62M | 58.61M | 49.98M | 47.1M | 40.32M | 32.22M | 2.57M | 1.12M |
| shares | — | 88.75M | 82.34M | 75.97M | 68.66M | 67.62M | 58.61M | 49.98M | 47.1M | 40.32M | 32.22M | 2.57M | 1.12M |
Italic rows are computed from reported lines — open a row's info icon for its formula. Values reflect the latest filing (restatements included); per-share figures on today's split basis. Click a value for its source filing.
TTM: trailing twelve months through the latest reported quarter — flows sum the last four quarters, balances take the latest. 3Y/5Y/10Y columns are trailing CAGR from the newest fiscal year; blank where an endpoint is missing or negative.
Price & Valuation
Multiples computed on the strict TTM/EV methodology — today's snapshot against the industry, and each ratio recomputed as of past filing dates.
Valuation
EV/Revenue
5.90×
Biotechnology median 8.54×
EV/EBIT
—
Biotechnology median 25.59×
P/E (TTM)
—
Biotechnology median 7.55×
Valuation over time computed as of each quarter's filing date
Revenue Breakdown
Annual revenue as the company disaggregates it in its own XBRL filings. Years a component wasn't reported show a dash.
Share mode is each component's slice of the reported components that year — issuers rarely tag every revenue dollar, so slices need not sum to total revenue.
By Segment (USD)
| Component | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Reportable Segment | $40,520,000 | $32,314,000 | $78,123,000 | $19,712,000 |
Segment Operating Income
Annual operating income by business segment, as tagged in the company's own XBRL filings. Segments need not sum to the consolidated figure — corporate costs and eliminations are typically unallocated.
By Segment (USD)
| Component | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|
| Reportable Segment | -$251,152,000 | -$169,181,000 | -$225,950,000 |
Operating Margin by Segment (%)
| Component | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|
| Reportable Segment | -777.2% | -216.6% | -1146.3% |
Key facts
CIK
1650664
CUSIP
28106W103
13F (30d)
12 filings
10 filers
Visit website
Investor relations